Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)

NCT06090656 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

88

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Bevacizumab combined with Sintilimab
PROCEDURE: Transcatheter arterial chemoembolization

Sponsor

Sun Yat-sen University